by renewvax-admin | Sep 20, 2023 | News
ReNewVax has been named ‘One to Watch’ in UKTN’s 2023 guide to University Spinouts. University spinouts are companies founded to commercialise innovative technologies, products or services that have originated from academic research conducted within universities....
by renewvax-admin | Sep 20, 2023 | News
ReNewVax’s Chief Scientific Officer Dr Marie O’Brien is published in this autumn’s edition of Drug Target Review, sharing insights into our quest for a universal pneumococcal vaccine. ‘Why innovation is the key to unlocking a universal pneumococcal vaccine’ details...
by renewvax-admin | Aug 2, 2023 | News
Since spinning out of the University of Liverpool, ReNewVax has started to build its scientific team and progressed its vaccine programme RVX-001 towards regulatory studies that will allow clinical trials to begin. CSO Dr. Marie O’Brien and CEO Dr. Neil Murray reflect...
by renewvax-admin | Jul 23, 2023 | News
This month, European Pharmaceutical Review features a piece from ReNewVax’s Chief Executive Dr. Neil Murray for its Formulation issue. In the piece, Neil explores the importance of new bacterial vaccines in the context of antimicrobial resistance and examines how the...
by renewvax-admin | Jun 22, 2023 | News
This month, North West Business Insider has named ReNewVax as one of thirty businesses across the region carrying out exciting work in their sectors. The Most Exciting Companies list features a range of companies shaking up their sectors, whether it be manufacturing,...
by renewvax-admin | May 5, 2023 | News
We’re thrilled to announce that ReNewVax has been shortlisted as one of the finalists to present a pitch at the 2023 BIO International Convention in Boston, Massachusetts. Taking place from 5th –8th June, the BIO International Convention is the world’s largest...
